Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening

Completed · Phase 3

Conditions studied: Smoking, Lung Cancer

In brief

In 2011, the National Lung Screening Trial (NLST) reported that lung cancer mortality was reduced by 20% with spiral computed tomography (CT) compared to chest X-ray. It is estimated that 8 million people in the US are at high risk for lung cancer and that lung screening could prevent 12,000 deaths annually. Cost effectiveness models suggest that concurrent smoking cessation programs will be essential in order to realize the full benefit of screening. However, there are no clinical guidelines or evidence-based cessation protocols with demonstrated effectiveness in this setting. The investigators are addressing this gap by rigorously testing whether two scalable and pragmatic interventions can significantly boost intention to quit and cessation rates.

Key facts

Study ID

NCT02267096

Run by

Georgetown University

People needed

95

Starts

2014-01-01

Expected to finish

2016-08-01

Last updated by the study team

2016-10-19

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 55-80 years old
• current smoker
• > 30-pack years
• English-speaking
• ability to provide meaningful consent
• enrolled to undergo lung cancer screening. -

You may not qualify if…

• history of lung cancer
• current treatment for other cancer -

Where it is running

• Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Lahey Hospital and Medical Center — Burlington, Massachusetts, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.